Rating History for Eli Lilly (LLY) by BMO Capital
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/6/2026 | Evan Seigerman | Maintain | Outperform (N/A) |
1,400.00 (1,300.00) |
|
Details | |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/6/2026 | Evan Seigerman | Maintain | Outperform (N/A) |
1,400.00 (1,300.00) |
|
Details | |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||